Results 51 to 60 of about 4,087,558 (297)

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

open access: yesMolecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son   +13 more
wiley   +1 more source

Late Diagnosis of Large Left Ventricular Pseudoaneurysm after Mitral Valve Replacement and Coronary Artery Bypass Surgery by Real-Time Three-Dimensional Echocardiography

open access: yesJournal of Tehran University Heart Center, 2015
One of the most serious complications of mitral valve replacement is left ventricular rupture and pseudoaneurysm formation, which is rare but potentially lethal.
Mohammad Sahebjam   +3 more
doaj  

Tardos fingerprinting is better than we thought

open access: yes, 2008
We review the fingerprinting scheme by Tardos and show that it has a much better performance than suggested by the proofs in Tardos' original paper. In particular, the length of the codewords can be significantly reduced. First we generalize the proofs
Celik, M.   +3 more
core   +2 more sources

Open Inflation Without False Vacua [PDF]

open access: yes, 1998
We show that within the framework of a definite proposal for the initial conditions for the universe, the Hartle-Hawking `no boundary' proposal, open inflation is generic and does not require any special properties of the inflaton potential.
Hawking, S. W., Turok, Neil
core   +2 more sources

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

open access: yesMolecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck   +12 more
wiley   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Tight lower bounds on the number of bicliques in false-twin-free graphs [PDF]

open access: yes, 2016
A \emph{biclique} is a maximal bipartite complete induced subgraph of $G$. Bicliques have been studied in the last years motivated by the large number of applications.
Groshaus, Marina, Montero, Leandro
core   +3 more sources

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

False Claims in Fight Over California's False Claims Act [PDF]

open access: yes, 2021
In this article, Ventry reviews the business lobbying efforts that derailed California legislation to amend the state’s False Claims Act by permitting tax claims.
Ventry, Dennis
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy